Astrazeneca and Vertex Join the Catalis Network CATALIS Quebec is very proud to announce that pharmaceutical companies AstraZeneca and Vertex are joining the CATALIS Network. As new members, they join Abbvie, Bayer, Boehriger Ingelheim, GSK, Merck, Novartis, Pfizer, Roche, Sanofi and Takeda. Together, the partners support CATALIS in its mission to optimize the clinical research environment to accelerate the
CATALIS’ Management Being Supported by Two New Advisory Committees Until recently, CATALIS’ management has been guided by three main advisory committees: a patient advisory committee made up of fifteen patient and patient-partner associations, a scientific and innovation advisory committee made up of expert clinical researchers, and an operations advisory committee made up of senior representatives from health institutions, pharmaceutical
CATALIS Quebec Partners With N2 Canada for Provincial Contract Access to the CITI-Canada Training Platform CATALIS Quebec is very proud to partner with N2 Canada to provide its Network member healthcare institutions access to a shared training platform designed to ensure the conduct of high-quality research: the CITI-Canada training platform. Through this partnership, CATALIS Quebec officially becomes the new
Two New Projects Successfully Authorized Within Seven Weeks Thanks to CATALIS QUEBEC’S FAST TRACK Evaluation Service While the first-ever FAST TRACK evaluation service pilot project was successfully completed last December, CATALIS is proud to announce that two more clinical trials have now been approved in record time. The second FAST TRACK evaluation service coordinated a Phase I oncology study
CATALIS Quebec’s Network of Partners Now Includes 23 Quebec Health Institutions In keeping with its new government mandate of bringing together clinical research stakeholders, CATALIS Quebec is pleased to announce that it is expanding the scope of its activities to a larger number of institutions in the province: it has added 23 public institutions from Quebec’s health and social
Three Major Projects Mark the Start of the Patient Advisory Committee’s Operations Patient partners and 11 patient organizations representing various medical conditions are at the core of CATALIS Quebec’s new Patient Advisory Committee. This committee was mandated by CATALIS management to identify common issues and solutions that will facilitate patient engagement and increase patient participation in, and referrals to, clinical
Patient Partners and 11 Patient Organizations Have Joined CATALIS Québec CATALIS Québec and its partners want the patient’s voice to be heard in all facets of clinical research in Quebec. As a result, we are now working with patient organizations and patient partners from various therapeutic fields by including them on our new patient advisory committee. In carrying out
CATALIS is launching a new call for applications to select public institutions that will receive 2 years of funding for their participation in CATALIS activities. Within the call for applications, public institutions that are members of the Table nationale des directeurs de recherche (TNDR) are invited to apply on 2 levels of clinical research activities: the implementation of automated tools
Boehringer Ingelheim and Sanofi Join the CATALIS Network New pharmaceutical industry partners are supporting CATALIS in making Quebec a world leader in clinical research. MONTREAL, May 20, 2021 —CATALIS Québec is proud to announce that two pharmaceutical companies, Boehringer Ingelheim and Sanofi, have joined its network of partners who are working together to support Quebec’s competitiveness in conducting clinical trials.
Quebec is a top destination for life sciences and clinical research. To strengthen our efforts to spread this message beyond Quebec, CATALIS Québec has joined The Coolest Hotspot network.
A team from the CHU de Québec-Université Laval has begun a clinical trial in order to develop new therapeutic options for the treatment of pancreatic adenocarcinoma, an aggressive cancer whose survival rate is less than one year.
The CHU de Québec-Université Laval (CRCHU) Research Centre has worked extra hard this year to stimulate launches of early-stage clinical research projects in the Quebec City region. The Research Centre is about to double the number of clinical trials conducted in its institutions.
Clinical trials, cell therapies and partnerships with different specialities: the hematology/oncology research team at the Hôpital de l’Enfant-Jésus (HEJ) in Quebec City is involved in all areas where research can make a difference for its patients.
On August 29th, the management team at the CHUM Research Centre officially opened its Unit for Innovative Therapies (UIT), a competitive infrastructure for early-stage clinical research in Canada.
CATALIS’s public and private partners join forces to make Quebec a global leader in the conduct of early-stage clinical trials.
The two organizations are joining forces to maximize the human and economic benefits of clinical trials province-wide.
Novartis and Roche Join the CATALIS Initiative Industry partnership will help establish Quebec as a global leader in early stage clinical research MONTREAL, February 6, 2019— The CATALIS initiative is proud to announce that pharmaceutical companies Novartis and Roche have joined its partner network. A mere two years after its creation, CATALIS Québec has succeeded in mobilizing Quebec’s key players
The CATALIS initiative celebrates new partners Private and public funding provide essential support and highlight Quebec’s role in the field of early stage clinical trials BOSTON, June 5th, 2018 – A year following its launch at the BIO conference in 2017, the CATALIS initiative is today proud to announce the arrival of new partners, both financial and medical, which will further
Progression of Quebec’s world-class Early Clinical Research Ecosystem Merck Canada provides financial and expert support to CATALIS MONTREAL, Quebec (May 9, 2018) – CATALIS is proud to announce that Merck Canada confirms financial and expert support for its early clinical research initiative. This support from Merck Canada contributes to the promotion of this world-class field of research in Quebec. “At